Ampio Offers Update on Phase III Multicenter, Double-Blind STEP Study of Ampion

By: via Benzinga
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™ ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.